Geographical and temporal patterns of cutaneous leishmaniasis in Pakistan: insight from a decade of epidemiology.

Trans R Soc Trop Med HygOct 5, 2026
Clinical ResearchInfectious DiseasesDermatology

Rehana Shaheen, Razia Bibi, Muhammad Aurongzeb et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the geographical distribution and epidemiological trends of cutaneous leishmaniasis (CL) in Pakistan from 2014 to 2024. A total of 27,380 confirmed cases were identified, with the highest prevalence in Khyber Pakhtunkhwa (60%). The annual incidence rate was reported at 8-10% over the decade.

Key findings

  • Khyber Pakhtunkhwa accounted for 60% of confirmed CL cases.
  • The annual incidence rate of CL was 8-10% over the past decade.
  • Approximately 60-65% of cases were male.
  • Diagnosis was primarily based on microscopy in 80% of cases.

Why it matters

Understanding the epidemiological patterns of cutaneous leishmaniasis is crucial for public health planning and resource allocation. Increased awareness and improved diagnostic methods can help mitigate the disease's impact in affected regions.

Source

PubMed · PMID 42565274

Published in Trans R Soc Trop Med Hyg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.